ReviewCureus2022
Sarcopenia and Endocrine Ageing: Are They Related?
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Association of handgrip strength with the plasma metabolomic profile: secondary analysis of a protein intervention study.Metabolomics : Official journal of the Metabolomic Society · 2026Trial
- Effect of whole-body vibration stimulation on plasma soluble TNF receptors in elderly with sarcopenia: a randomized controlled trial.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024Trial
- Integrin αVβ5 regulates myoblast proliferation and differentiation in sarcopenia mice treated with FNDC5 gene delivery : Original article.Skeletal muscle · 2026Article
- A Cross-Sectional Analysis of Musculoskeletal and Functional Outcomes in Patients with Pituitary Disorders: Frailty and Sarcopenia.Journal of clinical medicine · 2026Article
- Life activities of elderly patients with operated nonfunctional pituitary adenoma.Frontiers in endocrinology · 2026Article
- Sarcopenia in rheumatic and musculoskeletal diseases: pathophysiology, diagnosis, and management.Rheumatology international · 2025Review
- Advances in Nutritional and Therapeutic Strategies for Type 2 Intestinal Failure: A Narrative Review.Nutrition reviews · 2025Review
- Unravelling the Complexity of Sarcopenia Through a Systems Biology Approach.International journal of molecular sciences · 2025Review
- Challenges in identifying malnutrition in obesity; An overview of the state of the art and directions for future research.Nutrition research reviews · 2025Review
- Pathological and Inflammatory Consequences of Aging.Biomolecules · 2025Review
- Therapeutics for Sarcopenia and Functional Disabilities in Older Adults: A Review of Phase 4 Clinical Trials.Drug design, development and therapy · 2025Review
- Association between chronic kidney disease and sarcopenia and emerging treatment strategies.Frontiers in nutrition · 2025Review
- Effects of an Oral Nutritional Supplementation and Physical Exercise Intervention on Older Adults at Risk for Sarcopenia.Journal of frailty, sarcopenia and falls · 2024Article
- Sarcopenic obesity in older adults: a clinical overview.Nature reviews. Endocrinology · 2024Review
- Do we know about dynapenia?Northern clinics of Istanbul · 2024Review
- The Impact of Complex Rehabilitation Treatment on Sarcopenia-Pathology with an Endocrine Morphological Substrate and Musculoskeletal Implications.Medicina (Kaunas, Lithuania) · 2023Article
- Age-Related Hormones Changes and Its Impact on Health Status and Lifespan.Aging and disease · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is an illness of the elderly defined by a widespread and gradual decline of skeletal muscle mass and function, with the possibility of negative effects such as poor physical performance, decreased quality of life, and death. Sarcopenia has complicated and multiple pathogeneses. The shift in pathways necessary for muscle regeneration, inflammatory process, and protein synthesis appears to be one of the leading causes of loss of strength and muscle due to age. Researchers have discussed the effects of hypothalamic-pituitary dysfunction in this condition. Lifestyle factors like diet and exercise significantly influence body composition, physical function, and metabolic consequences. The effectiveness and tolerability of hormone replacement in treating sarcopenia will be determined through large-scale clinical trials. In this article, we present a summary of our current knowledge regarding the role of the endocrine system in sarcopenia and an overview of hormonal therapy to address endocrine abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.